Alan J. Lewis, Ph.D.
President and CEO, Juvenile Diabetes Research Foundation

Alan J. Lewis, Ph.D., joined the Juvenile Diabetes Research Foundation (JDRF) as President and CEO in January 2009. JDRF is a leader in setting the agenda for diabetes research worldwide, and is the largest charitable funder and advocate of type 1 research.

Prior to joining JDRF, Dr. Lewis served as President, CEO, and Director of Novocell, since 2006. Novocell is a stem cell engineering company dedicated to creating, delivering and commercializing cell and drug therapies to treat diabetes and other chronic diseases. Previously, Dr. Lewis served as CEO and Director of Signal Pharmaceuticals before its acquisition in 2000 by Celgene and then served as President of the Signal Research Division at Celgene. Prior, Dr. Lewis held the position of Vice President of Research at Wyeth-Ayerst.

Dr. Lewis serves as a Director of BioMarin Pharmaceutical, Cytochroma, Biotica Technology Ltd., and the Scottish Stem Cell Network. He received a B.Sc. in Physiology and Biochemistry from Southampton University, U.K., a Ph.D. in Pharmacology from the University of Wales–Cardiff, and completed his postdoctoral training at Yale University. He is also an Honorary Fellow and Chair of the Life Sciences Department at the University of Wales in Swansea.